Array Biopharma (ARRY) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2016
February 2, 2016 7:02 AM ESTBOULDER, Colo., Feb. 2, 2016 /PRNewswire/ --Â Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter ending December 31, 2015 of its fiscal year and provided an update on the progress of its key clinical development programs.
Ron Squarer, Chief Executive Officer of Array, noted, "We were excited this quarter to share positive results from the first global Phase 3 trial of binimetinib in... More



